Nemo and Flemming's Leadershiop will save us!

Quote




anonymous said:
Anyone who doubts Flemming is a wanker! Galderma has never been stronger.
Click to expand...
Flemming will save us all. He has done a great job so far. The IPO money I got changed my life and the 30% of my bonus this year was such a treat. Galderma has been so good to me. You never know who will be there the next day, which is a fun guessing game. It is alway so interesting. I love coming to the office after a long commute and no one is there. Wasting my time is great when it is for Flemming.
 




anonymous said:
Flemming will save us all. He has done a great job so far. The IPO money I got changed my life and the 30% of my bonus this year was such a treat. Galderma has been so good to me. You never know who will be there the next day, which is a fun guessing game. It is alway so interesting. I love coming to the office after a long commute and no one is there. Wasting my time is great when it is for Flemming.
Click to expand...
For anyone who has been wronged for any reason in their career and can't let it go;
remember it's not the snake bite that kills you, but the venom that remains in you. Focus on what you can control and leave the negativity behind.
Fuck Flemming!
 




Dupixent, Rinvoq, Adbry and Cibinqo all on the US market for Atopic Dermatitis. Order of entry is an important consideration. As 5th, Nemo can expect at best 8% share as 6th or beyond 2% share with an additional disadvantage for small pharma and lack of experience in the therapeutic area. Why does Galderma even bother given the high hurdles and high cost of entry? Or is it for Flemming‘s ego only?
 




anonymous said:
Dupixent, Rinvoq, Adbry and Cibinqo all on the US market for Atopic Dermatitis. Order of entry is an important consideration. As 5th, Nemo can expect at best 8% share as 6th or beyond 2% share with an additional disadvantage for small pharma and lack of experience in the therapeutic area. Why does Galderma even bother given the high hurdles and high cost of entry? Or is it for Flemming‘s ego only?
Click to expand...
This company has never sold a biologic or played in a highly competitive market. EQT will have a rude awakening when Nemolizumab sales fail to materialize.
 




anonymous said:
Flemming will save us all. He has done a great job so far. The IPO money I got changed my life and the 30% of my bonus this year was such a treat. Galderma has been so good to me. You never know who will be there the next day, which is a fun guessing game. It is alway so interesting. I love coming to the office after a long commute and no one is there. Wasting my time is great when it is for Flemming.
Click to expand...
Is it a fair question to ask if the return on our internal R&D investment is worth it? My guess is no based on what little I see come out of our R&D group. Nemo is not ours and it’s too late to market.
 








Top Bottom
Back
Quote